BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16859772)

  • 1. Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction.
    Niccoli G; Lanza GA; Spaziani C; Altamura L; Romagnoli E; Leone AM; Fusco B; Trani C; Burzotta F; Mazzari MA; Mongiardo R; Biasucci LM; Rebuzzi AG; Crea F
    Int J Cardiol; 2007 May; 117(3):306-11. PubMed ID: 16859772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The significance of admission hs-CRP in patients undergoing primary percutaneous intervention for acute myocardial infarction].
    Cağli KE; Topaloğlu S; Aras D; Günel EN; Ozlü MF; Uygur B; Baysal E; Sen N
    Turk Kardiyol Dern Ars; 2009 Jan; 37(1):19-25. PubMed ID: 19225249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: a retrospective study in patients undergoing primary percutaneous coronary intervention.
    Ishii H; Ichimiya S; Kanashiro M; Aoyama T; Ogawa Y; Murakami R; Amano T; Naruse K; Matsubara T; Murohara T
    Clin Ther; 2006 Nov; 28(11):1812-9. PubMed ID: 17213001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of ST-segment resolution after rescue percutaneous coronary intervention. Data from the RICO survey.
    Lorgis L; Zeller M; Dentan G; Laurent Y; Taam JA; L'Huillier I; Vincent-Martin M; Makki H; Cottin Y;
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):607-12. PubMed ID: 18360851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention.
    Niccoli G; Giubilato S; Russo E; Spaziani C; Leo A; Porto I; Leone AM; Burzotta F; Riondino S; Pulcinelli F; Biasucci LM; Crea F
    Eur Heart J; 2008 Aug; 29(15):1843-50. PubMed ID: 18617477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction.
    Fu XH; Fan WZ; Gu XS; Wei YY; Jiang YF; Wu WL; Li SQ; Hao GZ; Wei QM; Xue L
    Chin Med J (Engl); 2007 Jul; 120(14):1226-31. PubMed ID: 17697572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of prognostic value of epicardial blood flow and early ST-segment resolution after primary coronary angioplasty. ANIN--Myocardial Infarction Registry.
    Kalińczuk Ł; Przyłuski J; Karcz M; Petryka J; Kaczmarska E; Bekta P; Kepka C; Kruk M; Pregowski J; Kadziela J; Deptuch T; Skwarek M; Cedro K; Ciszewski M; Debski A; Ciszewski A; Chmielak Z; Demkow M; Witkowski A; Ruzyłło W
    Kardiol Pol; 2007 Jan; 65(1):1-10; discussion 11-2. PubMed ID: 17295155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High cholesterol in patients with ECG signs of no-reflow after myocardial infarction.
    Dobrzycki S; Kozuch M; Kamiński K; Korecki J; Ostasz A; Podgrudna E; Bonda T; Musiał WJ
    Rocz Akad Med Bialymst; 2003; 48():118-22. PubMed ID: 14737956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of direct stenting on epicardial and myocardial perfusion in patients with acute ST segment elevation myocardial infarction.
    Gasior M; Gierlotka M; Pres D; Lekston A; Zebik T; Hawranek M; Tajstra M; Stasik-Pres G; Kalarus Z; Poloński L
    Kardiol Pol; 2007 May; 65(5):503-12; discussion 513-4. PubMed ID: 17577847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging.
    Eitel I; Nowak M; Stehl C; Adams V; Fuernau G; Hildebrand L; Desch S; Schuler G; Thiele H
    Am Heart J; 2010 May; 159(5):882-90. PubMed ID: 20435200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization.
    Niccoli G; Lanza GA; Shaw S; Romagnoli E; Gioia D; Burzotta F; Trani C; Mazzari MA; Mongiardo R; De Vita M; Rebuzzi AG; Lüscher TF; Crea F
    Eur Heart J; 2006 Aug; 27(15):1793-8. PubMed ID: 16829540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Level of Selvester QRS score is predictive of ST-segment resolution and 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention.
    Uyarel H; Cam N; Okmen E; Kasikcioglu H; Tartan Z; Akgul O; Simsek D; Cetin M; Bozbeyoglu E; Buturak A; Uzunlar B
    Am Heart J; 2006 Jun; 151(6):1239.e1-7. PubMed ID: 16781226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction.
    Jeong YH; Kim WJ; Park DW; Choi BR; Lee SW; Kim YH; Lee CW; Hong MK; Kim JJ; Park SW; Park SJ
    Int J Cardiol; 2010 May; 141(2):175-81. PubMed ID: 19144424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty.
    Grabowski M; Filipiak KJ; Karpinski G; Wretowski D; Rdzanek A; Huczek Z; Horszczaruk GJ; Kochman J; Rudowski R; Opolski G
    Am Heart J; 2004 Oct; 148(4):655-62. PubMed ID: 15459597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
    Brener SJ; Westerhout CM; Fu Y; Todaro TG; Moliterno DJ; Wagner GS; Granger CB; Armstrong PW;
    Am Heart J; 2009 Nov; 158(5):755-60. PubMed ID: 19853693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of admission glomerular filtration rate on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction.
    Celik T; Iyisoy A; Yuksel CU; Kilic S; Yilmaz MI; Akgul EO; Jata B; Isik E
    Coron Artery Dis; 2008 Dec; 19(8):543-9. PubMed ID: 19005288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction.
    Tartan Z; Ozer N; Uyarel H; Akgul O; Gul M; Cetin M; Kasikcioglu H; Cam N
    Nutr Metab Cardiovasc Dis; 2008 Jul; 18(6):441-7. PubMed ID: 17981019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction.
    Pan W; Wang LF; Yu JH; Fan Y; Yang SS; Zhou LJ; Li Y; Li WM
    Chin Med J (Engl); 2009 Nov; 122(22):2718-23. PubMed ID: 19951602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Buller CE; Fu Y; Mahaffey KW; Todaro TG; Adams P; Westerhout CM; White HD; van 't Hof AW; Van de Werf FJ; Wagner GS; Granger CB; Armstrong PW
    Circulation; 2008 Sep; 118(13):1335-46. PubMed ID: 18779444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.